Coronary Artery Restenosis (DBCOND0032386)

Identifiers

Synonyms
Restenosis, Coronary / Coronary Restenosis / Coronary artery restenosis

Associated Data

Indicated Drugs and Targets
Not Available
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT03767621
Concordance Between FFR and iFR for the Assessment of Intermediate Lesions in the Left Main Coronary Artery. A Prospective Validation of a Default Value for iFRNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT04968977
PCI vs. CABG in UPLM-ISRNo drug interventionsNot AvailableNot Availablecompleted
NCT00531011
EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel DiseaseNo drug interventionstreatment4completed
NCT05860400
Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort StudyNo drug interventionsNot AvailableNot Availablerecruiting
NCT00496938
XIENCE V: SPIRIT WOMENNo drug interventionstreatment4completed
NCT01759290
ABSORB FIRST is a Registry Designed to Evaluate the Safety and Performance of Absorb Bioresorbable Vascular Scaffold (Absorb BVS) Used in Real-world Patients.No drug interventionsNot AvailableNot Availablecompleted
NCT00180479
SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)No drug interventionstreatment3completed
NCT01182428
XIENCE V: SPIRIT WOMEN Sub-studyNo drug interventionstreatment4completed
NCT01310309
EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel DiseaseNo drug interventionsNot AvailableNot Availablecompleted
NCT06007248
Disease Characteristics of IR-CAD: a Case-control StudyNo drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT05093244
Resveratrol Excipient Paclitaxel Coated Balloon for Coronary TreatmentNo drug interventionstreatmentNot Availablewithdrawn
NCT02300454
Effect of Combination of Non-sLip Element Balloon (NSE) and druG-coated bAlloon (DCB) for In-steNT Restenosis LesionsNo drug interventionstreatment4unknown_status
NCT03074305
DEB Versus 2nd Generation DES in Patients With In-Scaffold Restenosis of Bioresorbable Vascular ScaffoldNo drug interventionstreatmentNot Availablewithdrawn
NCT00859183
Oral Sirolimus for In-Stent Restenosistreatment4completed
NCT01331707
DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity in an All Comers PopulationNo drug interventionstreatment4completed
NCT02474485
Absorb BVS vs. Drug Coated Balloon for Treatment Of ISRNo drug interventionstreatmentNot Availablesuspended
NCT01894152
XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm StudyNo drug interventionsNot AvailableNot Availablecompleted
NCT00376870
PIoglitazone for PrEvention of Restenosis in Diabetic Patientstreatment3unknown_status
NCT01967199
Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent RestenosisNo drug interventionstreatment4terminated
NCT02175706
DUrable Polymer-based STent CHallenge of Promus ElemEnt Versus ReSolute IntegrityNo drug interventionstreatmentNot Availableunknown_status
NCT00426049
Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantationtreatment3unknown_status
NCT01274234
OCT Evaluation of Healing of COMBO StentNo drug interventionstreatment1 / 2completed
NCT01977534
To Study the Safety and Clinical Outcomes of the Absorb Bioresorbable Vascular Scaffold (BVS) System in Patients With de Novo Lesions in Previously Untreated VesselsNo drug interventionsNot AvailableNot Availablecompleted
NCT00162357
Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplastydiagnostic4completed
NCT00412126
Clinical and Angiographic Outcomes With Hyperglycemic Control Post PCItreatmentNot Availablecompleted
NCT00180466
PROSPECT: An Imaging Study in Patients With Unstable Atherosclerotic LesionsNo drug interventionsNot AvailableNot Availablecompleted
NCT01915420
The ASSURE ROT Registry: Bioresorbable Vascular Scaffold Following Rotablation for Complex Coronary LesionsNo drug interventionsNot AvailableNot Availableunknown_status
NCT01171820
SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study)No drug interventionstreatment4completed
NCT00287573
Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent RestenosisNo drug interventionstreatment2 / 3completed
NCT01249027
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm StudyNo drug interventionsNot AvailableNot Availablecompleted
NCT01205776
EXCEL Clinical TrialNo drug interventionstreatmentNot Availablecompleted
NCT04915391
Restenosis in Coronary Stents And Cutaneous HEaLingNo drug interventionsNot AvailableNot Availableunknown_status
NCT00752362
Per-cutaneous Intervention Based Paclitaxel and Sirolimus-Eluting Versus Bare Stents for the Treatment of de Novo Coronary Lesions (PAINT)No drug interventionstreatment4completed
NCT01205789
EXCEL Clinical Trial (Universal Registry)No drug interventionsNot AvailableNot Availablecompleted
NCT01023789
ABSORB EXTEND Clinical InvestigationNo drug interventionstreatmentNot Availablecompleted
NCT01178268
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)No drug interventionstreatment4completed
NCT00180310
SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent SystemNo drug interventionstreatment3completed
NCT00055510
A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.treatment2 / 3completed
NCT02508714
Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX StentsNo drug interventionstreatmentNot Availableunknown_status
NCT04494750
Physiology and Residual Ischemia After Percutaneous Coronary InterventionNo drug interventionsNot AvailableNot Availableunknown_status
NCT01066650
The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in TwenteNo drug interventionstreatment4completed
NCT00243308
Serp-1 for the Treatment of Acute Coronary Syndromediagnostic2terminated
NCT01583608
ABSORB: Postmarketing Surveillance Registry to Monitor the Everolimus-eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery DiseaseNo drug interventionsNot AvailableNot Availablecompleted
NCT00124943
Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosistreatment1 / 2completed
NCT01262703
Safety Study of a Bioresorbable Coronary StentNo drug interventionstreatmentNot Availablecompleted
NCT01674803
Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion (BIO-RESORT)No drug interventionstreatmentNot Availablecompleted
NCT02944890
Compare the Efficacy and Safety of RESTORE DEB and SeQuent® Please in Chinese Patient With Coronary In-stent RestenosisNo drug interventionstreatmentNot Availablecompleted
NCT01651390
Clinical Performance of the Pantera Lux Balloon Versus the Orsiro Stent in Patients With In-stent Restenosis.No drug interventionstreatmentNot Availablecompleted
NCT00500279
Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trialtreatment4unknown_status
NCT00106587
Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH - ISR I)treatment1 / 2completed
NCT01115933
A Clinical Evaluation of the XIENCE PRIME Small Vessel Everolimus Eluting Coronary Stent System in Japanese PopulationNo drug interventionstreatmentNot Availablecompleted
NCT00714545
SCRIPPS V: Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting StentsNo drug interventionstreatment4completed
NCT05471245
AnGiographic Performance With A Sirolimus-elutiNG Balloon in the TrEatment of De Novo CoronaRy Artery DiseaseNo drug interventionstreatmentNot Availablerecruiting
NCT00631228
XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm StudyNo drug interventionsNot AvailableNot Availablecompleted
NCT01086228
XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for JapanNo drug interventionsNot AvailableNot Availablecompleted
NCT00856856
ABSORB Clinical Investigation, Cohort BNo drug interventionstreatmentNot Availablecompleted
NCT00148356
Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary ArteriesNo drug interventionstreatment2 / 3completed
NCT04988685
SIROOP Registry - A Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated With SIROlimus Or Paclitaxel Eluting Balloon CathetersNo drug interventionsNot AvailableNot Availablerecruiting
NCT00916370
SPIRIT PRIME Clinical TrialNo drug interventionstreatment3completed
NCT01269242
The Effects of Bindarit in Preventing Stent Restenosisprevention2completed
NCT02263313
EGO-COMBO Clinical End-point Extension Study Beyond 36 MonthsNo drug interventionsNot AvailableNot Availablecompleted
NCT03667313
Treatment of In-Stent Restenosis 2 Studytreatment3completed
NCT00882219
Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up PeriodNo drug interventionstreatment3completed
NCT01106534
XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohorttreatment4completed
NCT03242096
Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated or a Paclitaxel Coated BalloontreatmentNot Availablecompleted
NCT00248066
Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary ArteriesNo drug interventionstreatment2completed
NCT00300131
ABSORB Clinical Investigation, Cohort A (ABSORB A) Everolimus Eluting Coronary Stent System Clinical InvestigationNo drug interventionsNot AvailableNot Availablecompleted
NCT04475380
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting StentsNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT04280029
SELUTION SLR™ 014 In-stent RestenosisNo drug interventionstreatmentNot Availableactive_not_recruiting
NCT00140101
Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary ArteriesNo drug interventionsprevention2completed
NCT00402272
SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in EuropeNo drug interventionstreatment4completed
NCT00552669
Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stentshealth_services_research4completed
NCT02151812
Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR)No drug interventionstreatmentNot Availablecompleted
NCT00589810
Whole Genome Association Study to Identify and Validate Genes for Restenosis: CardioGene Validation ProposalNo drug interventionsNot AvailableNot Availablecompleted
NCT00409981
Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH - ISR II)No drug interventionstreatment1 / 2completed
NCT02367495
Trial of a Novel Paclitaxel-coated Balloon With Citrate Excipient for Restenosis in -Limus Analogue DESNo drug interventionstreatmentNot Availablecompleted
NCT00714623
The SCRIPPS DES REAL WORLD RegistryNo drug interventionsNot AvailableNot Availablecompleted
NCT05089864
STAR and Deferred Stenting StudyNo drug interventionstreatmentNot Availablerecruiting
NCT06075602
COMPLEX Registry - A Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting With compLEX and Calcified Coronary Artery DiseaseNo drug interventionsNot AvailableNot Availablerecruiting
NCT01120379
XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)No drug interventionsNot AvailableNot Availablecompleted